1 active not recruiting. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Active not recruiting 1 |
Follow HIV Seropositivity: new trials by email Literature Review of HIV Seropositivity trials Research Report on HIV Seropositivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients Daily rifapentine and isoniazid for 4 weeks, Weekly rifapentine and isoniazid for 12 weeks - HIV Seropositivity, Tuberculosis | Phase 4 | Active not recruiting | The Aurum Institute NPC | 1000 | 2023-07-19 | 2025-12-12 |
Tuberculosis (1)
Actinomycetales Infections (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · Gram-Positive Bacterial Infections (1) · HIV Infections (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Infections (1) · Lentivirus Infections (1) · Mycobacterium Infections (1) · RNA Virus Infections (1) · Retroviridae Infections (1)
Isoniazid (1)
India (1) · Indonesia (1) · Mozambique (1) · South Africa (1)
Gavin Churchyard (1)